Janet Sawicki, PhD, who held the deputy director’s position for the past nine years, will retain her role as a principal investigator at LIMR.
Dr. Gilmour, who has been at LIMR since 1990, is a cancer researcher well known for her work on polyamines, a class of nutrients for which all cancers have a voracious appetite. Recognized as a leader in this field, she was elected by her peers worldwide to chair the 2017 Polyamines Gordon Conference. Throughout her career, her overarching goal has been to translate her basic research findings into therapies that can contribute to increased survival in cancer patients.
Her latest work led to the discovery of a novel polyamine-blocking therapy that boosts the immune response against cancers. This new line of research builds on LIMR’s pioneering work in the field of immunometabolic therapies for cancer treatment—an area that is contributing to the explosion of promising results using immunotherapies as new tools to eradicate previously incurable cancers.
“Dr. Gilmour has been a faculty leader at LIMR for many years, and we are thrilled for her to step into the role of deputy director,” said George Prendergast, PhD, president and CEO of LIMR. “Her extensive experience in grant funding, scientific collaboration and inventions will be applied in broader directions to help advance the institute’s mission.”
Dr. Gilmour earned a bachelor’s degree in biology at the University of Virginia where she was also a member of the first women’s varsity crew team. She earned her PhD in toxicology and pharmacology from Rutgers University/University of Medicine and Dentistry, followed by a postdoctoral fellowship in molecular carcinogenesis at The Wistar Institute in Philadelphia. In addition to her roles at LIMR, she is a member of the Sidney Kimmel Cancer Center at Thomas Jefferson University and is an adjunct professor of pathology at Drexel University where she regularly mentors students in her lab.
Dr. Gilmour noted, “I am excited about my new responsibilities here at LIMR, and I plan to expand my efforts to strengthen research at LIMR and to be of service to the institute and to Main Line Health. At the same time, I know I join everyone at LIMR in thanking Dr. Sawicki for her service to the institute.”
For more than 26 years, Dr. Gilmour’s research has been supported by funding from the National Institutes of Health (NIH). She also has received multiple additional grants including those from the US Department of Defense (DOD), Boehringer Ingelheim, the W.W. Smith Charitable Trust, and the Sharpe-Strumia Research Foundation. She has served on numerous study sections to review grants for both NIH and DOD. And her research has been published in many peer-reviewed publications, including Cancer Research, Oncotarget, and Cancer Immunology Research.
Founded in 1985, Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. Main Line Health’s commitment—to deliver advanced medicine to treat and cure disease while also playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to keep our community and ourselves well ahead. A team of more than 10,000 employees and 2,000 physicians care for patients throughout the Main Line Health system.
At Main Line Health’s core are four of the region’s most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s recognized facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.
The Main Line Health system also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region’s largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence, the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award, and recognition as among the nation’s best employers by Forbes magazine. Main Line Health is committed to creating an environment of diversity, respect and inclusion and has proudly embraced the American Hospital Association’s #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help our community stay healthy.
About Lankenau Institute for Medical Research
Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.